gemcitabine

#Italian real-world evidence of #durvalumab, gemcitabine, cisplatin in advanced #biliarytractcancer #cholangiocarcinoma #CCA #BTC ⁦@LiverInt⁩ ⁦@casadei_gardini⁩ ⁦@lonardi_sara⁩ ⁦@Mom_enji⁩ ⁦@HUNIMED⁩ ⁦@HumanitasMilano⁩ https://t.co/ENsCg2QXMK (@LorenzaRimassa)

Our last paper—> Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data @LorenzaRimassa @sara_lonardi1 @Mom_enji @fedenichetti https://t.co/5aHbvCT7Bd (@casadei_gardini)

@DanengLi, MD, discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab. What are your thoughts on this case? #gicsm | @cityofhope https://t.co/ibhA0HJtfT https://t.co/L860Tf97dX (@TargetedOnc)

Here is our international collaborative work on FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer ⁦@AnnSurgOncol⁩ ⁦@SocSurgOnc⁩ ⁦@SSATNews⁩ ⁦@FlavioRochaMD⁩ ⁦ https://t.co/4ALnMZQuI3 (@SyedAAhmad5)

Great to be part of this novel approach for patients with pancreatic cancer. @MPishvaian - look forward to the presentation at #ESMO23. #PancreaticCancer LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. con... https://t.co/L2ShXoS4WZ (@KarynAGoodman)

I have metastatic and locally advanced bladder carcinoma, with PA proven metastatis in left acetabulum (pT4N2M1) and (PDL1 CPS<10). Since CT 20-06-2022 I have partial remission after 6 x carboplatin and gemcitabine and 6 x gemcitabine. (@ClemensLaseur)

Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer @MPishvaian @HopkinsMedicine @myESMO @WCGIC #WCGIC2023 #pancsm https://t.co/Dw9CrSO3w6 (@OncLive)

Nutide-121 in #WCGIC2023 shows NO benefit of NUC-1032 in #BiliaryCancer @hospitalclinic 🤨Dissapointing results with a lot of toxicity also We have to look for the best option… (@TamaraSN2)

Nutide-121 in #WCGIC2023 shows NO benefit of NUC-1032 in #BiliaryCancer 😕 Dissapointing results, but a very important study 🤷🏻‍♀️Rational was there and had to be tested ✍️Highlights the relevance of performing randomised studies (when feasible 😉) (@DrAngelaLamarca)

Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121) by Jennifer Knox at #WCGIC2023 👉Interesting rationale, but very disappointing 👉mOS 9.2 vs 12.6 mo (control arm) & more Tox… https://t.co/dw1dL30Npf (@ArndtVogel)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/hCLD2Q81YP (@OncLive)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/AI03UpN2Va (@OncLive)

4- A multicenter, open-label, randomized phase It study evaluating adjuvant gemcitabine plus Cisplatin vs capecitabine with concurrent capecitabine radiotherapy (CAPE-RT) in patients with operated gallbladder adenoca @AnantRamaswamy (@Prasshmehta)

Updated analysis reveals improved overall survival from combination of gemcitabine/ATR inhibition in platinum-resistant #OvarianCancer - especially in tumors with low replication stress. #ASCO23 #gyncsm (@ShannonWestin)

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC) @ASCO. @MPishvaian @edikb @PanCAN #mPDAC #ASCO23 #Perthera #PrecisionMedicine (@Perthera)

Validation of the PDACai signature in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC). https://t.co/wAL7n7LC7e Visit our poster session #ASCO23 @MPishvaian @edikb (@Perthera)

Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer https://t.co/oSRtkxiJbP (@MLPOncoData)

A modified regimen of biweekly gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer is both tolerable and effective: a retrospective analysis https://t.co/HCrIIddQ4I (@MLPOncoData)

Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis https://t.co/xUamDFYrTN (@MLPOncoData)

Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis https://t.co/DJA02t8cGK (@MLPOncoData)

Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry https://t.co/7HkZUELijQ (@MLPOncoData)

Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma https://t.co/ah9BenEKMS (@MLPOncoData)

Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer https://t.co/nblzlpLFmx (@MLPOncoData)

Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma https://t.co/iem7C2ydKC (@MLPOncoData)

Biweekly Gemcitabine/Nab-Paclitaxel as First-line Treatment for Advanced Pancreatic Cancer https://t.co/1sqi5gUrK1 (@MLPOncoData)

DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma [2023] Liebner et al. #ASCO23 Abst 11578, Poster 512 https://t.co/LXktCqxb6z #scmsm @OSUCCC_James @TempusLabs (@mtmdphd)

In a small cohort of patients with MIBC with sarcomatoid variant receiving neoadjuvant cisplatin/gemcitabine/docetaxel showed pT0 in 4/6 patients at cystectomy @HopkinsMedicine @djmcconkey (@arkhaki)

DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma [2023] Liebner et al. #ASCO23 Abst 11578, Poster 512 https://t.co/LXktCqxb6z #scmsm @OSUCCC_James @TempusLabs (@mtmdphd)

We report on 2 cases of exceptional response to combination gemcitabine+sirolimus after failure of nab-sirolimus and gemcitabine mono in TSC-mutated #sarcoma ↪️Molecular rationale support combination of these drugs! @MDAndersonNews @NeetaSomaiahMD https://t.co/rlbr0c1lqM (@NassifElise)

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) https://t.co/zxTUspxDid (@VivekSubbiah)

In @JAMANetworkOpen from @JamesClearyMD: No improvement in PFS, OS or ORR of a MUC5AC Antibody (NPC-1C) Combined with 2nd Line Gemcitabine Nab-Paclitaxel in Patients With Advanced #PancreaticCancer All received 1st line FOLFIRINOX Cases had >20% MUC5AC+ https://t.co/FVgYrrySw2 (@Aiims1742)

I will be more keen to use cisplatin or carboplatin in combination with gemcitabine in those 5 to 8 % of pancreatic cancer with brca1 /2 mutations . May work better than Olaparib. (@SuyogCancer)

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14) - The Lancet Gastroenterology & Hepatology https://t.co/AbGR0xlECV (@doctorC369)

Why aren’t @GSK @GSKUS fast tracking the development of SRA737 given it showed COMPLETE TUMOUR REGRESSION IN SMALL CELL LUNG CANCER when combined with low dose gemcitabine and PD-L1? The results speak for themselves. SRA737 sat gathering dust for 2 years with Sierra Oncology (@sra737PRTeam)

When will SRA737 be discussed? The highly selective and potent Chk1 inhibitor now owned by @GSK @GSKUS that showed complete tumour regression in small cell lung cancer when combined with low dose gemcitabine and PD-L1? Gathered dust for 2 years at Sierra Oncology. #SCLC (@sra737PRTeam)

@GSK now own SRA737, the highly potent and selective Chk1 inhibitor. Showed complete tumour regression in small cell lung cancer when combined with low dose gemcitabine and PD-L1. When will GSK progress this life saver? #lungcancer #SCLC (@sra737PRTeam)

IMMUCHEC trial in naïve cholangio-/gallbladder carcinoma ✅Adding IO (durvalumab +/- tremelimumab) to chemo (gemcitabine/cisplatin) did not improve efficacy ➡️Subgroup with dominant PD-1 in immune cells seems to benefit more from the combo @ArndtVogel @EASLedu @OncoAlert #ESMO22 (@AMalfettonePhD)

👍Growing armamentarium against #BRCA mutated #pancreaticcancer 👉Gemcitabin/Cisplatin https://t.co/GyJCL8uGjn 👉Olaparib https://t.co/I9yElqqxPf 👉Niraparib/Ipilimumab https://t.co/72j0e7B4Nx 👉Nivolumab/Ipilimumab https://t.co/IHrVFW1X2D ✅promising! @myESMO @OncoAlert (@ArndtVogel)

Combination therapy with #piperlongumine and #gemcitabine is a promising treatment option💊 for KRAS mutant #lungcancer #LCSM 🫁 Learn more 🔗https://t.co/PPOHkkTTiZ @manjuggm @DrSanjayPopat @FSkoulidis #oncology #MedTwitter #MedEd (@TumoriJ)

@DrArsenOsipov proud to say my @CSCancerCare #GIonc partner is a poster discussant at #ASCO22 1) PhI/II maint nira + ipi effective in non-DDR adv #pancsm, 2) PhIII mFFX + Devimistat vs FFX negative met #PDAC, 3) Ph1/2a anti-IL1RAP + gem/abrax active in adv #pancsm @DrHendifar (@jgong15)

#AACR22 @mserenaroca recipient #Pezcoller travelaward present Repurposing of #valproicacid and #simvastatin in #pancreaticcancer: in vitro and in vivo synergistic antitumor interaction and sensitization to gemcitabine/nab-paclitaxel via inhibition of TGFβ-EMT signaling pathway (@AlfredoBudillon)

⁦@mserenaroca⁩ #AACR22 11/4 #1840 Repurposing of valproic acid and simvastatin in pancreatic cancer: in vitro and in vivo synergistic antitumor interaction and sensitization to gemcitabine/nab-paclitaxel via inhibition of TGFβ-EMT signaling pathway https://t.co/eSqyxJx43Z (@AlfredoBudillon)